OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Long non-coding RNA mediated drug resistance in breast cancer
Deepshikha Singh, Yehuda G. Assaraf, Rajesh N. Gacche
Drug Resistance Updates (2022) Vol. 63, pp. 100851-100851
Closed Access | Times Cited: 83
Deepshikha Singh, Yehuda G. Assaraf, Rajesh N. Gacche
Drug Resistance Updates (2022) Vol. 63, pp. 100851-100851
Closed Access | Times Cited: 83
Showing 1-25 of 83 citing articles:
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance
Xu Guo, Congying Gao, Dong‐Hua Yang, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100937-100937
Closed Access | Times Cited: 92
Xu Guo, Congying Gao, Dong‐Hua Yang, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100937-100937
Closed Access | Times Cited: 92
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update
Emine Bayraktar, Recep Bayraktar, Hülya Öztatlıcı, et al.
Non-Coding RNA (2023) Vol. 9, Iss. 2, pp. 27-27
Open Access | Times Cited: 53
Emine Bayraktar, Recep Bayraktar, Hülya Öztatlıcı, et al.
Non-Coding RNA (2023) Vol. 9, Iss. 2, pp. 27-27
Open Access | Times Cited: 53
lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways
Raed Obaid Saleh, Mushtak T.S. Al-Ouqaili, Eyhab Ali, et al.
Medical Oncology (2024) Vol. 41, Iss. 2
Closed Access | Times Cited: 15
Raed Obaid Saleh, Mushtak T.S. Al-Ouqaili, Eyhab Ali, et al.
Medical Oncology (2024) Vol. 41, Iss. 2
Closed Access | Times Cited: 15
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 49
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 49
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
Novel epirubicin-loaded nanoformulations: Advancements in polymeric nanocarriers for efficient targeted cellular and subcellular anticancer drug delivery
Mehrab Pourmadadi, Shima Ostovar, Gustavo Ruiz-Pulido, et al.
Inorganic Chemistry Communications (2023) Vol. 155, pp. 110999-110999
Closed Access | Times Cited: 36
Mehrab Pourmadadi, Shima Ostovar, Gustavo Ruiz-Pulido, et al.
Inorganic Chemistry Communications (2023) Vol. 155, pp. 110999-110999
Closed Access | Times Cited: 36
Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy
Bolong Tao, Ruoxin Du, Xiangmei Zhang, et al.
Journal of Controlled Release (2023) Vol. 363, pp. 692-706
Closed Access | Times Cited: 36
Bolong Tao, Ruoxin Du, Xiangmei Zhang, et al.
Journal of Controlled Release (2023) Vol. 363, pp. 692-706
Closed Access | Times Cited: 36
Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation
Yuan Gao, Man Tong, Tin Lok Wong, et al.
ACS Nano (2023) Vol. 17, Iss. 22, pp. 22240-22258
Closed Access | Times Cited: 33
Yuan Gao, Man Tong, Tin Lok Wong, et al.
ACS Nano (2023) Vol. 17, Iss. 22, pp. 22240-22258
Closed Access | Times Cited: 33
The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms
Malihe Rezaee, Fatemeh Mohammadi, Atoosa Keshavarzmotamed, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 29
Malihe Rezaee, Fatemeh Mohammadi, Atoosa Keshavarzmotamed, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 29
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs
Xing Peng, Shuo Wang, Yu Cao, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 101002-101002
Open Access | Times Cited: 21
Xing Peng, Shuo Wang, Yu Cao, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 101002-101002
Open Access | Times Cited: 21
Long noncoding RNA H19: functions and mechanisms in regulating programmed cell death in cancer
Yuyang Xia, Tianjiao Pei, Junjie Zhao, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Yuyang Xia, Tianjiao Pei, Junjie Zhao, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
Binglei Zhang, Jianxiang Shi, Xiaojing Shi, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101068-101068
Closed Access | Times Cited: 8
Binglei Zhang, Jianxiang Shi, Xiaojing Shi, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101068-101068
Closed Access | Times Cited: 8
Natural products reverse cancer multidrug resistance
Jiayu Zou, Qilei Chen, Xiao-Ci Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
Jiayu Zou, Qilei Chen, Xiao-Ci Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer
Yue Pan, Qianqian Zhang, Hongwei Zhang, et al.
Functional & Integrative Genomics (2023) Vol. 23, Iss. 1
Closed Access | Times Cited: 17
Yue Pan, Qianqian Zhang, Hongwei Zhang, et al.
Functional & Integrative Genomics (2023) Vol. 23, Iss. 1
Closed Access | Times Cited: 17
CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20
Jiahui Sun, Ruoxin Du, Xiaoju Li, et al.
Cancer Letters (2024) Vol. 588, pp. 216747-216747
Open Access | Times Cited: 6
Jiahui Sun, Ruoxin Du, Xiaoju Li, et al.
Cancer Letters (2024) Vol. 588, pp. 216747-216747
Open Access | Times Cited: 6
Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms
Yue Shi, Joseph Adu‐Amankwaah, Qizhong Zhao, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27207-e27207
Open Access | Times Cited: 6
Yue Shi, Joseph Adu‐Amankwaah, Qizhong Zhao, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27207-e27207
Open Access | Times Cited: 6
LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer
Junya Arima, Hirofumi Yoshino, Wataru Fukumoto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5955-5955
Open Access | Times Cited: 6
Junya Arima, Hirofumi Yoshino, Wataru Fukumoto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5955-5955
Open Access | Times Cited: 6
Exercise-downregulated CD300E acted as a negative prognostic implication and tumor-promoted role in pan-cancer
Zhiwen Luo, Jin-guo Zhu, Rui Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Zhiwen Luo, Jin-guo Zhu, Rui Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm
Jing Zhang, Le Wu, Chenchen Wang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 1385-1398
Open Access | Times Cited: 5
Jing Zhang, Le Wu, Chenchen Wang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 1385-1398
Open Access | Times Cited: 5
Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer
Chenlin Liu, Fan Dong, Jiahui Sun, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access
Chenlin Liu, Fan Dong, Jiahui Sun, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access
Delving Into lncRNA‐Mediated Regulation of Autophagy‐Associated Signaling Pathways in the Context of Breast Cancer
Chou‐Yi Hsu, Saade Abdalkareem Jasim, Pooja Bansal, et al.
Cell Biology International (2025)
Closed Access
Chou‐Yi Hsu, Saade Abdalkareem Jasim, Pooja Bansal, et al.
Cell Biology International (2025)
Closed Access
Innovative Approaches in Atherosclerosis Treatment: Harnessing Traditional Chinese Medicine to Target Long Non-Coding RNAs
Xiaofang Chen, Wen‐yan Ding, Yifan Liu, et al.
Phytomedicine (2025) Vol. 139, pp. 156488-156488
Closed Access
Xiaofang Chen, Wen‐yan Ding, Yifan Liu, et al.
Phytomedicine (2025) Vol. 139, pp. 156488-156488
Closed Access
Layered Double Hydroxide LDH-Loaded miR-141–3p Targets RAB10 Suppressing Cellular Autophagy to Reverse Paclitaxel Resistance in Breast Cancer
Shuang Tao, Yuxin Ji, Ruonan Li, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 5886-5899
Open Access
Shuang Tao, Yuxin Ji, Ruonan Li, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 5886-5899
Open Access
STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis
Yihui Pan, Shuang Liu, Guannan Shu, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Yihui Pan, Shuang Liu, Guannan Shu, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Epigenetic Landscapes of Aging in Breast Cancer Survivors: Unraveling the Impact of Therapeutic Interventions—A Scoping Review
Nikita Nikita, Zhengyang Sun, Swapnil Sharma, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 866-866
Open Access
Nikita Nikita, Zhengyang Sun, Swapnil Sharma, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 866-866
Open Access
